Linagliptin as Add on Therapy to Empagliflozin 10 mg or 25 mg With Japanese Patients With Type 2 Diabetes Mellitus

Boehringer Ingelheim880 enrolled

Overview

Two independent study parts (i.e. Part A and Part B) are included in this trial. Part A will evaluate empagliflozin 10 mg + linagliptin and Part B will evaluate empagliflozin 25 mg + linagliptin. All analyses will be carried out separately for these study parts. The objective of Part A is to investigate the efficacy, safety and tolerability of the fixed dose combination (FDC) of empagliflozin 10 mg / linagliptin 5 mg compared with empagliflozin 10 mg plus FDC matching placebo administered orally once daily for 24 weeks in Japanese patients with T2DM (Type 2 Diabetes Mellitus) who have insufficient glycaemic control after 16 weeks of treatment with empagliflozin 10 mg alone once daily. The study is designed to show superiority of the FDC of empagliflozin 10 mg / linagliptin 5 mg over empagliflozin 10 mg plus FDC matching placebo after 24 weeks of treatment. The objective of Part B is to investigate the efficacy, safety and tolerability of the FDC of empagliflozin 25 mg / linagliptin 5 mg compared with empagliflozin 25 mg plus FDC matching placebo administered orally once daily for 24 weeks in Japanese patients with T2DM who have insufficient glycaemic control after 16 weeks of treatment with empagliflozin 25 mg alone once daily. The study is designed to show superiority of the FDC of empagliflozin 25 mg / linagliptin 5 mg over empagliflozin 25 mg plus FDC matching placebo after 24 weeks of treatment. The 24 week treatment period will be followed by a 28 week extension treatment period to evaluate further efficacy and safety up to 52 weeks.

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

DOUBLE

Enrollment

880

Conditions

Diabetes Mellitus, Type 2

Interventions

empagliflozin 10 mg + linagliptin 5 mgDRUG

empagliflozin low dose + linagliptin once daily

empagliflozin 10 mgDRUG

empagliflozin low dose once daily

empagliflozin 25 mg + linagliptin 5 mgDRUG

empagliflozin high dose + linagliptin once daily

empagliflozin 25 mgDRUG

empagliflozin high dose once daily

PlaceboDRUG

Eligibility

Sex: ALLMin age: 20 Years

Medical Language ↔ Plain English

Inclusion criteria: * Diagnosis of type 2 diabetes prior to informed consent * Male and female patients on diet and exercise regimen for at least 12 weeks prior to informed consent who are: * drug-naïve, defined as no antidiabetic drugs for at least 12 weeks prior to informed consent or, * pre-treated with one oral antidiabetic drug (for sulfonylurea, with up to half of the maximum approved dose) on stable dosage for at least 12 weeks prior to the informed consent (for thiazolidinedione, therapy has to be unchanged for at least 18 weeks prior to the informed consent). Individual antidiabetic drug will have to be discontinued at Visit 1. * haemoglobin A1c (HbA1c) at Visit 1 (screening) * for patients without antidiabetic therapy : HbA1c \>=8.0 to =\<10.5% * for patients with one oral antidiabetic drug : HbA1c \>=7.5 to =\<10.5% * HbA1c \>=7.5 to =\<10.0% at Visit 4 for randomisation into the double blind treatment period Exclusion criteria: * Uncontrolled hyperglycaemia with a glucose level \>270 mg/dL (\>15.0 mmol/L) during the open label stabilisation period and placebo run in period * Impaired renal function, defined as estimated glomerular filtration rate (eGFR) \<45 mL/min/1.73m2 (modification of diet in renal disease (MDRD) formula) * Acute coronary syndrome, stroke or transient ischemic attack (TIA) within 12 weeks prior to informed consent * Indication of liver disease, defined by serum levels of either alanine transaminase (ALT), aspartate transaminase (AST), or alkaline phosphatase (ALP) above 3 x upper limit of normal (ULN)

Locations (83)

Tokai Memorial Hospital

Aichi, Kasugai, Japan

Japan Organization of Occupational Health and Safety Chubu Rosai Hospital

Aichi, Nagoya, Japan

Tokuyama Clinic

Chiba, Chiba, Japan

Matsuyama Shimin Hospital

Ehime, Matsuyama, Japan

Tanaka Int. Clinic, Ehime, DIA Med.,CV Med.

Ehime, Niihama, Japan

Outcomes

Primary Outcomes

Change in Glycated Haemoglobin A1c (HbA1c) (%) From Baseline After 24 Weeks of Treatment

Change from baseline in HbA1c (%) after 24 weeks of treatment with double-blind trial medication. Change was calculated as: HbA1c value at 24-week - HbA1c value at baseline, for each patient. Baseline was defined as the last observation before the first intake of double-blind randomised trial medication. Statistical analysis presented is based on a restricted maximum likelihood (REML)-based mixed model repeated measures (MMRM) approach. Full Analysis Set (Observed Cases) \[FAS (OC)\]: This analysis set consisted of all patients who were randomised and treated with at least 1 dose of trial drug during the double-blind part of the trial and who had a baseline HbA1c assessment and at least 1 on-treatment HbA1c assessment during the 24-week double-blind part of the trial. Observed cases analysis included only the available data that were observed while patients were on treatment, i.e., excluding the missing data.

Time frame: Baseline and 24 week